KR880001815A - Monoclonal Antibody against Pseudomonas aeruginosa flagella - Google Patents

Abstract

No content

Description

Monoclonal Antibody against Pseudomonas aeruginosa flagella

As this is a public information case, the full text was not included.

Claims (35)

In particular, a composition comprising monoclonal antibodies or binding fragments capable of reacting with Pseudomonas aeruginosa bacterial flagella. The composition according to example 1, wherein the monoclonal antibody or binding fragment inhibits the motility of the bacteria. In particular, a composition comprising monoclonal antibodies capable of reacting with flagella protein epitopes of Pseudomonas aeruginosa. A.T.C.C. The composition according to example 4, which is a monoclonal antibody capable of blocking binding to epitopes of monoclonal antibodies produced by cell lines designated as acceptance numbers HB 9129, HB 9130, CRL 9300 and CRL 9301. A composition, wherein the monoclonal antibody mentioned first consists of at least one monoclonal antibody which reacts with an epitope of flagella form a Pseudomonas aeruginosa or flagella form b Pseudomonas aeruginosa. The composition according to example 6, wherein the second mentioned monoclonal antibody can react with flagella form a, which does not react at first. The composition according to Example 6, wherein the first mentioned monoclonal antibody is a human monoclonal antibody. The composition according to example 6, wherein at least one of the monoclonal antibodies mentioned is protective in vivo. A composition according to any one of claims 1,4,6 or 8, consisting of gamma globulin fragments obtained from human plasma and / or antibiotics. A pharmaceutical composition comprising the composition according to any one of claims 1, 4, 6 or 8 and a physiologically acceptable carrier. Treats Pseudomonas aeruginosa infection, which is a composition consisting of a protective monoclonal antibody, a biocide, a gamma globulin fragment obtained from human plasma, and a pharmaceutically acceptable carrier, which react with the flagella protein of Pseudomonas aeruginosa. Or contractual compositions useful for preventing or preventing. The antibody according to Example 12, wherein the antibody is a human monoclonal antibody and a gamma globulin fragment obtained from human plasma is obtained from a human who exhibits high levels of immunoglobulins that react with Pseudomonas aeruginosa bacteria and / or their products. Pharmaceutical compositions. A pharmaceutical composition comprising at least two monoclonal antibodies that specifically react with Pseudomonas aeruginosa flagella proteins of different forms, and which can treat or prevent Pseudomonas aeruginosa infection. The composition according to claim 14, wherein at least one monoclonal antibody is a human monoclonal antibody. The composition according to claim 14, consisting of at least one human monoclonal antibody capable of reacting with at least one serotype determinant on a lipopolysaccharide molecule of Pseudomonas aeruginosa and / or a monoclonal antibody reacting with exotoxin A. A method of treating such people, comprising administering to a person susceptible to bacteremia and / or pulmonary disease in an amount suitable to prevent or treat the composition according to any one of claims 1, 6, 8, 12, 14 or 15. A cell line that produces monoclonal antibodies that can specifically react with Pseudomonas aeruginosa flagella form a or Pseudomonas aeruginosa flagella form b. The cell line according to claim 18, wherein the monoclonal antibody protects against Pseudomonas aeruginosa in vivo. The cell line according to claim 19, which is a hybrid cell line. The cell line according to claim 18, which produces a human monoclonal antibody. A.T.C.C. The cell line according to claim 18, which is one of the acceptance numbers HB 9129, HB 9130 or CRL 9300 and CRL 9301. A method of producing monoclonal antibodies specific for the flagella protein of Pseudomonas aeruginosa and capable of treating or preventing Pseudomonas aeruginosa infection, comprising culturing at least one of the cell lines of claim 22 to harvest the mentioned antibody. Way. A method of treating such a person, comprising administering to a person prone to bacteremia or pulmonary disease an amount suitable to prevent or treat the monoclonal antibody produced according to claim 23. A monoclonal antibody or fragment that reacts with an epitope capable of binding to the monoclonal antibody produced according to claim 23. A composition comprising monoclonal antibodies of humans that specifically react with epitopes present in Pseudomonas aeruginosa flagella. The composition according to claim 26, wherein the epitope is present in flagella form a or flagella form b, but not in both. The composition according to claim 26, wherein the epitope is represented by at least 70% flagella form b. The composition according to claim 26, wherein the epitope is represented solely by flagella form b. The composition according to claim 29, wherein the antibody is pre-reactive. Prophylactic amount or amount of monoclonal antibody that can react with toxin A of the Pseudomonas aeruginosa bacteria in humans susceptible to bacterial infection: or with at least one serotype crystal on the lipopolysaccharide molecule of Pseudomonas aeruginosa Capable of monoclonal antibody; Or gamma globulin fragments obtained from human blood serum; Or gamma globulins obtained from plasma of humans exhibiting high levels of immunoglobulins that react with Pseudomonas eruginosa and / or products thereof; Or administering an amount in a quantity suitable to prevent or treat monoclonal antibodies capable of binding to the flagella of Pseudomonas aeruginosa in cooperation with one or more of the fungicides. A monoclonal antibody composition having the same binding-specificity as any of the monoclonal antibodies designated FA6 IIG5, Pa3IVC2, PaF4IVE8, 20H11 or 21B8. The monoclonal antibody according to claim 32 conjugated to a label capable of presenting a detectable symbol. The monoclonal antibody according to claim 33, wherein the label is a fluorescent agent or an enzyme. A method for determining the presence of Pseudomonas aeruginosa in a sample consisting of combining a sample with a monoclonal antibody that reacts with Pseudomonas aeruginosa flagella and detecting a complex structure. Pseudomonas et al, wherein the antibody binds to a specific form flagella protein of the Pseudomonas aeruginosa bacterium and binds the label covalently with the mentioned antibody or with a second antibody that reacts with each monoclonal antibody. A tool comprising a monoclonal antibody composition comprising at least one monoclonal antibody for use in detecting the presence of luginosa bacteria. ※ Note: The disclosure is based on the initial application.